Home » Stocks » CLSD

Clearside Biomedical, Inc. (CLSD)

Stock Price: $1.72 USD -0.06 (-3.37%)
Updated November 23, 4:00 PM EST - Market closed
After-hours: $1.55 -0.17 (-9.88%) Nov 23, 7:36 PM

Stock Price Chart

Key Info

Market Cap 83.17M
Revenue (ttm) 9.83M
Net Income (ttm) -14.19M
Shares Out 48.35M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $1.72
Previous Close $1.78
Change ($) -0.06
Change (%) -3.37%
Day's Open 1.78
Day's Range 1.72 - 1.79
Day's Volume 62,403
52-Week Range 0.99 - 4.13

More Stats

Market Cap 83.17M
Enterprise Value 70.02M
Earnings Date (est) Mar 16, 2021
Ex-Dividend Date n/a
Shares Outstanding 48.35M
Float 35.69M
EPS (basic) -0.31
EPS (diluted) -0.32
FCF / Share -0.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.45M
Short Ratio 13.60
Short % of Float 4.05%
Beta 1.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.47
PB Ratio 10.54
Revenue 9.83M
Operating Income -14.11M
Net Income -14.19M
Free Cash Flow -7.05M
Net Cash 13.15M
Net Cash / Share 0.27
Gross Margin 22.12%
Operating Margin -143.62%
Profit Margin -144.50%
FCF Margin -71.76%
ROA -39.97%
ROE -158.74%
ROIC 435.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 3
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$5.50*
(219.77% upside)
Low
3.00
Current: $1.72
High
8.00
Target: 5.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue2.170.030.350.52--
Revenue Growth7143.33%-91.3%-33.65%---
Gross Profit2.170.030.350.52--
Operating Income-30.30-82.95-58.41-25.20-17.64-10.19
Net Income-30.77-82.82-58.98-25.88-17.64-10.19
Shares Outstanding38.1730.7325.3113.112.341.74
Earnings Per Share-0.81-2.69-2.33-1.97-7.54-5.86
Operating Cash Flow-27.07-79.20-51.08-22.71-13.90-9.12
Capital Expenditures-0.03-0.09-0.31--0.03-0.14
Free Cash Flow-27.09-79.29-51.39-22.71-13.93-9.26
Cash & Equivalents22.9641.2438.0083.9920.28-
Total Debt6.419.988.017.595.98-
Net Cash / Debt16.5531.2629.9976.4114.31-
Assets26.7844.1240.4984.8121.06-
Liabilities15.6220.5019.0813.1510.40-
Book Value11.1623.6221.4271.66-36.66-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Clearside Biomedical, Inc.
Country United States
Employees 33
CEO George M. Lasezkay

Stock Information

Ticker Symbol CLSD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLSD
IPO Date June 2, 2016

Description

Clearside Biomedical, a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.